Securities Fraud Lawsuit Filed Against uniQure N.V. Over 49% Stock Drop Following FDA Approval Delay
summarizeSummary
A securities fraud class action lawsuit has been filed against uniQure N.V. and certain executives, alleging failure to disclose material information regarding the likelihood of FDA accelerated approval for its lead drug candidate, AMT-130. The lawsuit covers the period between September 24 and October 31, 2025, and stems from the company's November 3, 2025, disclosure that the FDA no longer agreed that Phase I/II data for AMT-130 was adequate for a BLA submission, which caused a 49% stock decline. This legal action follows the company's earlier announcement on March 2, 2026, that the FDA rejected its BLA pathway for AMT-130. The lawsuit introduces significant legal and financial risk for uniQure, potentially leading to substantial costs and settlements, and further reinforces negative sentiment around the company's lead gene therapy program. Investors should monitor the lawsuit's progress and any related company disclosures.
At the time of this announcement, QURE was trading at $15.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $980.7M. The 52-week trading range was $7.76 to $71.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Access Newswire.